Men who carry a BRCA2 mutation (BRCA2+ men or BRCA2 carriers) have an increased risk for prostate cancer, also tumors are more aggressive. The results of the international IMPACT study show that the BRCA2+ men can have benefit from screening. A total of 2,932 men were recruited. After four screening rounds, BRCA2 carriers have been shown to have a statistically significant higher risk of prostate cancer, 19 per 1,000, compared to non-carriers, 12 per 1,000 (p = 0.03). It is also more often clinically significant prostate cancer (77%) compared to 49% in the general population. Based on the results of the IMPACT study, it was decided to actively discuss the possibility of screening for prostate cancer with BRCA2+ men in the Netherlands.

Additional Metadata
Keywords BRCA2 mutation, IMPACT study, prostate cancer, screening
Persistent URL dx.doi.org/10.1007/s13629-020-00280-0, hdl.handle.net/1765/125040
Journal Tijdschrift voor Urologie
Citation
van Asperen, C.J. (C. J.), & Bangma, C.H. (2020). Screening for prostate cancer in men with a BRCA2 mutation: recommendations for daily practice based on the results of an international study Screening naar prostaatkanker bij mannen met een BRCA2 mutatie: adviezen voor de praktijk gebaseerd op resultaten van internationale studie. Tijdschrift voor Urologie. doi:10.1007/s13629-020-00280-0